AEON (AEON Biopharma) EBITDA Margin %: 0.00% (As of Mar. 2026)


AEON AEON Biopharma Inc AEON
10 GF Score
Price $0.72
! 2 Warning Signs
View Full Analysis

What is AEON Biopharma EBITDA Margin %?

AEON Biopharma AEON +4.62% 10 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates AEON with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, AEON Biopharma ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. AEON Biopharma's EBITDA for the three months ended in Mar. 2026 was $-5.92 Mil. AEON Biopharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, AEON Biopharma's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

AEON Biopharma  (AMEX:AEON) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

AEON Biopharma EBITDA Margin % Related Terms

AEON Biopharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for AEON Biopharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AEON Biopharma EBITDA Margin % Chart

AEON Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

AEON Biopharma Quarterly Data
Dec19 Dec20 Jun21 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AEON vs GRTX, XCUR, ANEB: EBITDA Margin % Comparison

For the Biotechnology subindustry, AEON Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEON Biopharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEON Biopharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where AEON Biopharma's EBITDA Margin % falls into.


AEON
10GF Score
AEON Biopharma Inc AEON
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AEON Biopharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

AEON Biopharma's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-16.224/0
= %

AEON Biopharma's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-5.918/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
AEON Biopharma (AEON) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AEON Biopharma and its competitors. According to the industry distribution chart, AEON Biopharma ranks #999999 out of 944 companies in the Biotechnology industry.
Is AEON Biopharma's EBITDA Margin % too high?
AEON Biopharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, AEON Biopharma ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AEON Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does AEON Biopharma's EBITDA Margin % compare to GRTX and XCUR?
According to the Biotechnology industry distribution chart, AEON Biopharma ranks #999999 out of 944 companies for EBITDA Margin %. This places AEON Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AEON Biopharma and its competitors. AEON Biopharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AEON Biopharma stock overvalued right now?
AEON Biopharma (AEON) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. AEON Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For AEON Biopharma (AEON), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AEON Biopharma Business Description

Address 5 Park Plaza, Suite 1750, Irvine, CA, USA, 92614
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
10GF Score

Get the complete analysis for AEON

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price